Company news

Cocrystal Pharma, Inc. (NASDAQ:COCP) news

Cocrystal Pharma, Inc. news releases on 6ix. Latest, Mar 5, 2024: Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value…

Cocrystal Pharma, Inc. (NASDAQ:COCP) news

Press releases — page 2

Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap

Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates

Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023

Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs

Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Cocrystal Pharma Receives UK MHRA Authorization to Initiate Its Phase 2a Influenza Human Challenge Trial with Oral PB2 Inhibitor CC-42344

Cocrystal Pharma Doses First Subjects in Clinical Study of CDI-988 For Pandemic Norovirus and Coronavirus

Cocrystal Pharma to Participate in the H.C. Wainwright Global Investment Conference

Cocrystal Pharma Reports Second Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs

Cocrystal Pharma Selects Novel Oral Protease Inhibitor CDI-988 as Norovirus Lead

Cocrystal Pharma Receives HREC Approval to Initiate Phase 1 Study to Evaluate Oral Broad-Spectrum Coronavirus 3CL Protease Inhibitor CDI-988

Cocrystal Pharma Reports First Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs

Cocrystal Pharma Presents New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group Conference

Cocrystal Pharma Appoints Pharma Industry Veteran Fred Hassan to its Board of Directors

Cocrystal Pharma to Present New Data from its CC-42344 Phase 1 Influenza A Study at the 7th Annual ISIRV Antiviral Group Conference

Cocrystal Pharma Completes $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Cocrystal Pharma Reports 2022 Financial Results and Provides Updates on its Antiviral Drug Development Programs

Cocrystal Pharma to Highlights Progress with Its Antiviral Portfolio at the Virtual Investor Summit on March 29, 2023

Cocrystal Pharma Announces Participation in Virtual Investor Events

Cocrystal Pharma Discusses Clinical Progress and Significance of Its Novel Antiviral Therapeutics Pipeline with The Stock Day Podcast

Cocrystal Pharma Reports Highly Favorable Safety and Tolerability Results from a Phase 1 Study with its Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

Cocrystal Pharma Highlights Progress with CC-42344 as a Potential Oral Treatment for Pandemic and Seasonal Influenza A at the World Antiviral Congress 2022

Cocrystal Pharma Announces Favorable Safety Data from the Phase 1 Study with Oral Antiviral CC-42344 for the Treatment of Pandemic and Seasonal Influenza A

Cocrystal Pharma Reports Third Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs

Cocrystal Pharma to Participate in Two Investor Conferences in November

Cocrystal Pharma Granted European Patent Covering Oral Antiviral Candidate CC-42344 in Combination with Another Antiviral Agent for the Treatment of Influenza

Enrollment Completed in Phase 1 Influenza A Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344

Cocrystal Pharma to Present at the LD Micro Main Event XV

Cocrystal Pharma to Present CC-42344 Phase 1 Influenza A Data at the World Antiviral Congress 2022

Cocrystal Pharma Selects CDI-988 for Clinical Development as an Oral Treatment for COVID-19

Cocrystal Pharma to Present at the Dawson James Securities 2022 Small Cap Growth Conference

Cocrystal Pharma Announces a 1-for-12 Reverse Stock Split

Cocrystal Pharma Reports Second Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs

Cocrystal Pharma Engages CRO to Conduct Phase 2a Human Challenge Influenza A Clinical Trial with Novel, Broad-Spectrum Antiviral Candidate CC-42344

Cocrystal Pharma Discusses Therapeutic Platform Applications and Progress with The Stock Day Podcast

Cocrystal Pharma Reports CC-42344 Pharmacokinetic Data in Influenza A Once-Daily Dosing

Cocrystal Pharma Expands Collaboration with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors

Cocrystal Pharma to Present at the H.C. Wainwright Global Investment Conference

Cocrystal Pharma Reports First Quarter 2022 Financial Results and Provides Updates on its Antiviral Development Programs and Milestones

Cocrystal Pharma Collaborates with the National Institute of Allergy and Infectious Diseases to Evaluate COVID-19 Protease Inhibitors

Cocrystal Pharma to Present at the Life Science Innovation Northwest 2022 Conference

Cocrystal Pharma to Present at the Noble Capital Markets’ NobleCon18 Conference

Cocrystal Pharma Reports Favorable Preliminary Data from Phase 1 Initial Cohorts with CC-42344, a Novel, Broad-Spectrum Influenza A antiviral

Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones

Cocrystal Pharma to Participate in the Maxim Group 2022 Virtual Growth Conference

Cocrystal Pharma Initiates Enrollment in Phase 1 Influenza A Study with Novel, Broad-Spectrum, Orally Administrated Antiviral CC-42344

Cocrystal Pharma to Participate in Upcoming Investment Conferences

Cocrystal Pharma Selects Two Lead Antiviral Drug Candidates for its COVID-19 Oral Drug Program